Cargando…

How are growth hormone and insulin-like growth factor-1 reported as markers for drug effectiveness in clinical acromegaly research? A comprehensive methodologic review

OBJECTIVE: In rare disease research, most randomized prospective clinical trials can only use limited number of patients and are comprised of highly heterogeneous populations. Therefore, it is crucial to report the results in such a manner that it allows for comparison of treatment effectiveness and...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Esdonk, Michiel J., van Zutphen, Eline J. M., Roelfsema, Ferdinand, Pereira, Alberto M., van der Graaf, Piet H., Biermasz, Nienke R., Stevens, Jasper, Burggraaf, Jacobus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5942341/ https://www.ncbi.nlm.nih.gov/pubmed/29605877 http://dx.doi.org/10.1007/s11102-018-0884-4

Ejemplares similares

Model informed quantification of the feed‐forward stimulation of growth hormone by growth hormone‐releasing hormone
por: van Esdonk, Michiel J., et al.
Publicado: (2020)

Quantification of the endogenous growth hormone and prolactin lowering effects of a somatostatin-dopamine chimera using population PK/PD modeling
por: van Esdonk, Michiel J., et al.
Publicado: (2020)

A two-step deconvolution-analysis-informed population pharmacodynamic modeling approach for drugs targeting pulsatile endogenous compounds
por: van Esdonk, Michiel J., et al.
Publicado: (2017)

Acromegaly caused by growth hormone-releasing hormone-producing tumors: long-term observational studies in three patients
por: Biermasz, Nienke R., et al.
Publicado: (2007)

Limited effects of growth hormone replacement in patients with GH deficiency during long-term cure of acromegaly
por: van der Klaauw, Agatha A., et al.
Publicado: (2009)

Nanomedicines in the treatment of acromegaly: focus on pegvisomant
por: Roelfsema, Ferdinand, et al.
Publicado: (2006)

Therapeutic options in the management of acromegaly: focus on lanreotide Autogel(®)
por: Roelfsema, Ferdinand, et al.
Publicado: (2008)

Treatment of Acromegaly: Are We Satisfied With the Current Outcome?
por: Roelfsema, Ferdinand
Publicado: (2014)

The power of modelling pulsatile profiles
por: van Esdonk, Michiel J., et al.
Publicado: (2021)

Clinical factors involved in the recurrence of pituitary adenomas after surgical remission: a structured review and meta-analysis
por: Roelfsema, Ferdinand, et al.
Publicado: (2011)

Predictors of Quality of Life in Acromegaly: No Consensus on Biochemical Parameters
por: Geraedts, Victor J., et al.
Publicado: (2017)

The Oral Pheneticillin Absorption Test: An Accurate Method to Identify Patients with Inadequate Oral Pheneticillin Absorption
por: Dijkmans, Anneke C., et al.
Publicado: (2019)

Dose escalations in phase I studies: Feasibility of interpreting blinded pharmacodynamic data
por: Hassing, Gerardus J., et al.
Publicado: (2022)

Using Growth Hormone Levels to Detect Macroadenoma in Patients with Acromegaly
por: Park, Ji Young, et al.
Publicado: (2014)

Twenty‐four‐hour growth hormone profiling in the assessment of acromegaly
por: D'Arcy, Robert, et al.
Publicado: (2017)

Acromegaly Caused by Ectopic Growth Hormone Releasing Hormone Secretion: A Review
por: Zendran, Iga, et al.
Publicado: (2022)

Growth hormone secretion is diminished and tightly controlled in humans enriched for familial longevity
por: van der Spoel, Evie, et al.
Publicado: (2016)

Clinical and radiographic assessment of peripheral joints in controlled acromegaly
por: Pelsma, Iris C. M., et al.
Publicado: (2022)

Growth Hormone Secretion Does Not Increase After Interleukin-2 Administration in Healthy Men
por: Roelfsema, Ferdinand, et al.
Publicado: (2021)

Pituitary-hormone secretion by thyrotropinomas
por: Roelfsema, Ferdinand, et al.
Publicado: (2008)

Normalization of plasma growth hormone alleviated malignant ventricular tachycardia in acromegaly
por: Liu, Zhi-Hao, et al.
Publicado: (2018)

Low sclerostin levels after long-term remission of acromegaly
por: Claessen, Kim M. J. A., et al.
Publicado: (2021)

Growth hormone deficiency, acromegaly and COVID-19: Transitioning from media reports to knowledge and a growth hormone hypothesis
por: Yuen, Kevin C.J.
Publicado: (2021)

Low prevalence of neuropathic-like pain symptoms in long-term controlled acromegaly
por: van Trigt, Victoria R., et al.
Publicado: (2021)

Molecular Characterization of Growth Hormone-producing Tumors in the GC Rat Model of Acromegaly
por: Martín-Rodríguez, Juan F., et al.
Publicado: (2015)

Erectile Dysfunction Is Associated With Excessive Growth Hormone Levels in Male Patients With Acromegaly
por: Chen, Zhengyuan, et al.
Publicado: (2021)

Improvement in Symptoms and Health-Related Quality of Life in Acromegaly Patients: A Systematic Review and Meta-Analysis
por: Broersen, Leonie H A, et al.
Publicado: (2020)

Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly
por: Schmid, Herbert A., et al.
Publicado: (2016)

3D DXA Hip Differences in Patients with Acromegaly or Adult Growth Hormone Deficiency
por: Gracia-Marco, Luis, et al.
Publicado: (2021)

Delirium, insulin-like growth factor I, growth hormone in older inpatients
por: Adamis, Dimitrios, et al.
Publicado: (2020)

State of the Art of Patient-reported Outcomes in Acromegaly or GH Deficiency: A Systematic Review and Meta-analysis
por: van der Meulen, Merel, et al.
Publicado: (2021)

An exploratory first‐in‐man study to investigate the pharmacokinetics and safety of liposomal dexamethasone at a 2‐ and 1‐week interval in patients with metastatic castration resistant prostate cancer
por: Vrouwe, Josephina P. M., et al.
Publicado: (2021)

Relationships Between 24-hour LH and Testosterone Concentrations and With Other Pituitary Hormones in Healthy Older Men
por: van der Spoel, Evie, et al.
Publicado: (2021)

Relationship Between 24-Hour Serum LH and Testosterone Concentrations and Their Interrelationships With Other Pituitary Hormones in Healthy Older Men
por: van der Spoel, Evie, et al.
Publicado: (2021)

Patient-reported outcomes in refractory hormone-producing pituitary adenomas: an unmet need
por: van Trigt, Victoria R., et al.
Publicado: (2023)

Insulin Resistance in Patients With Acromegaly
por: Vila, Greisa, et al.
Publicado: (2019)

Association between the Growth Hormone Receptor Exon 3 Polymorphism and Metabolic Factors in Korean Patients with Acromegaly
por: Park, Hye Yoon, et al.
Publicado: (2015)

Population Pharmacokinetic/Pharmacodynamic Analysis of Nociceptive Pain Models Following an Oral Pregabalin Dose Administration to Healthy Subjects
por: van Esdonk, Michiel J., et al.
Publicado: (2018)

Clinicopathological Features of Growth Hormone-Producing Pituitary Adenomas in 242 Acromegaly Patients: Classification according to Hormone Production and Cytokeratin Distribution
por: Mori, Ryosuke, et al.
Publicado: (2013)

Acromegaly presenting with low insulin-like growth factor-1 levels and diabetes: a case report
por: Wijayaratne, Dilushi Rowena, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_u3tcqbrm56qjrauk9k8eobr754